BI 1744 CL 2 µg
1222.22
Phase 2 small_molecule completed
Quick answer
BI 1744 CL 2 µg for Pulmonary Disease, Chronic Obstructive is a Phase 2 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Pulmonary Disease, Chronic Obstructive
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed